neoTCR T cells in tumour biopsy samples after treatment
tumour
INFILTRATION, TUMOUR
In addition to the biopsy sample provided at screening for neoantigen prediction and identification, patients provided a baseline biopsy sample (day 5–7 before lymphodepletion) to assess continued neoantigen gene expression, and a biopsy sample after infusion (day 5–7 or day 28) to analyse for neoTCR transgenic T cell infiltration. Of the eight patients with longitudinal biopsy samples available for analyses, 13 out of the 19 predicted truncal neoantigen targets were detected from biopsy samples provided at the screening and baseline steps (Extended Data Fig. Sequence quantification of the TCR complementary-determining region 3 (CDR3) was performed on tumour biopsy samples taken before and after infusion (Fig. 